Polymyositis

Top Story

YKL-40 seen as promising biomarker for polymyositis, dermatomyositis-associated interstitial lung disease

July 20, 2017

YKL-40 could serve as a biomarker for patients with polymyositis/dermatomyositis-associated interstitial lung disease, according to a recently published study.

“Together, these findings suggest that YKL-40 is a promising non-invasive biomarker for evaluating disease activity/severity, predicting prognosis and clarifying the pathogenesis of [polymyositis/dermatomyositis-associated interstitial lung disease] PM/DM-ILD,” Hironao Hozumi, MD, PhD, from the Hamamatsu University School of Medicine, and colleagues wrote.

In the Journals

Patients with dermatomyositis, anti-NXP-2 antibodies have severe phenotype

February 13, 2017
Patients with dermatomyositis and anti-NXP-2 antibodies had a severe systemic phenotype, which included myalgia, peripheral edema and significant dysphagia, according to…
In the Journals

Baseline shoulder ultrasonography did not predict glucocorticoid response in patients with polymyalgia

February 2, 2017
Baseline shoulder ultrasonography was not predictive of glucocorticoid response in patients with polymyalgia rheumatica after 12 months, according to results of a…
In the Journals

Population-based study: Low annual incidence of mixed connective tissue disease

December 8, 2016
Based on a cohort in Minnesota from 1985 through 2014, researchers found the yearly occurrence of mixed connective tissue disease to be two people per 100,000. Using…
CME

Psoriatic Arthritis

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with psoriatic arthritis.
More »
Video
Meeting News

VIDEO: Lohmander calls for individualized exercise therapy for patients with OA

May 15, 2017
More »
Resource Centers
Biosimilars in the US

Biosimilars in the US

Advertisement
Advertisement